JP6223824B2 - 新規な自己反応性アーム及び同物を含むプロドラッグ - Google Patents

新規な自己反応性アーム及び同物を含むプロドラッグ Download PDF

Info

Publication number
JP6223824B2
JP6223824B2 JP2013510716A JP2013510716A JP6223824B2 JP 6223824 B2 JP6223824 B2 JP 6223824B2 JP 2013510716 A JP2013510716 A JP 2013510716A JP 2013510716 A JP2013510716 A JP 2013510716A JP 6223824 B2 JP6223824 B2 JP 6223824B2
Authority
JP
Japan
Prior art keywords
group
compound
present
reactive
self
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013510716A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013532132A (ja
JP2013532132A5 (enExample
Inventor
パポット，セバスティアン
トマス，ミカエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Poitiers
Original Assignee
Universite de Poitiers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Poitiers filed Critical Universite de Poitiers
Publication of JP2013532132A publication Critical patent/JP2013532132A/ja
Publication of JP2013532132A5 publication Critical patent/JP2013532132A5/ja
Application granted granted Critical
Publication of JP6223824B2 publication Critical patent/JP6223824B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/13—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups
    • C07C205/20—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings
    • C07C205/21—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings having nitro groups and hydroxy groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C205/22—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings having nitro groups and hydroxy groups bound to carbon atoms of the same non-condensed six-membered aromatic ring having one nitro groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2013510716A 2010-05-20 2011-05-18 新規な自己反応性アーム及び同物を含むプロドラッグ Active JP6223824B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1053921 2010-05-20
FR1053921A FR2960153B1 (fr) 2010-05-20 2010-05-20 Nouveaux bras autoreactifs et prodrogues les comprenant
PCT/IB2011/052184 WO2011145068A1 (fr) 2010-05-20 2011-05-18 Nouveaux bras autoréactifs et prodrogues les comprenant

Publications (3)

Publication Number Publication Date
JP2013532132A JP2013532132A (ja) 2013-08-15
JP2013532132A5 JP2013532132A5 (enExample) 2014-06-26
JP6223824B2 true JP6223824B2 (ja) 2017-11-01

Family

ID=43063203

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013510716A Active JP6223824B2 (ja) 2010-05-20 2011-05-18 新規な自己反応性アーム及び同物を含むプロドラッグ

Country Status (7)

Country Link
US (1) US9000135B2 (enExample)
EP (1) EP2571528B1 (enExample)
JP (1) JP6223824B2 (enExample)
CA (1) CA2799773C (enExample)
ES (1) ES2666562T3 (enExample)
FR (1) FR2960153B1 (enExample)
WO (1) WO2011145068A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3017298B1 (fr) * 2014-02-07 2016-03-04 Centre Nat Rech Scient Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires
KR101628872B1 (ko) 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
ES2785551T3 (es) 2014-06-30 2020-10-07 Glykos Finland Oy Derivado de sacárido de una carga útil tóxica y sus conjugados con anticuerpos
WO2016144814A1 (en) * 2015-03-06 2016-09-15 Colorado State University Research Foundation Synthesis and utility of new capgroup largazole analogs
KR102368068B1 (ko) 2015-08-24 2022-02-25 삼성전자주식회사 반도체 소자 제조용 조성물 및 이를 이용하는 반도체 소자의 제조 방법
CA3006249A1 (en) * 2015-11-25 2017-06-01 Legochem Biosciences, Inc. Antibody-drug conjugates comprising branched linkers and methods related thereto
WO2017089894A1 (en) 2015-11-25 2017-06-01 Legochem Biosciences, Inc. Conjugates comprising peptide groups and methods related thereto
HRP20240795T1 (hr) 2015-11-25 2024-09-13 Ligachem Biosciences Inc. Konjugati koji se sastoje od samozapaljujućih skupina i postupci povezani s njima
KR102085798B1 (ko) 2016-12-28 2020-03-06 주식회사 인투셀 베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물
IL269535B2 (en) 2017-03-29 2024-11-01 Ligachem Biosciences Inc Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same
EP3624854A1 (en) 2017-05-16 2020-03-25 Université de Strasbourg Protein-drug conjugates and their use in the treatment of cancers
HUE068574T2 (hu) * 2018-04-03 2025-01-28 Syndivia Citotoxikus hatóanyag konjugátuma és az említett konjugátum prodrugja
EP3790591A4 (en) 2018-05-09 2022-05-11 LegoChem Biosciences, Inc. Compositions and methods related to anti-cd19 antibody drug conjugates
KR102258299B1 (ko) * 2019-03-21 2021-05-28 고려대학교 산학협력단 대장암 선택적 항암 치료진단제
KR20210028544A (ko) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
WO2022140144A1 (en) 2020-12-21 2022-06-30 Colorado State University Research Foundation Synthesis of structural analogs of largazole and associated compounds
WO2022150721A1 (en) * 2021-01-08 2022-07-14 Lycia Therapeutics, Inc. Bifunctional folate receptor binding compounds
AU2022248565A1 (en) 2021-03-30 2023-10-05 Centre National De La Recherche Scientifique - Cnrs - Enzyme-triggered self-reacting linker having improved physicochemical and pharmacological properties
CN117957020A (zh) 2021-07-14 2024-04-30 利西亚治疗公司 Asgpr细胞表面受体结合化合物和缀合物
FR3126982B1 (fr) 2021-09-14 2023-09-15 Centre Nat Rech Scient Vecteurs ciblant la beta-d-n-acetylglucosaminidase
WO2024238912A1 (en) * 2023-05-17 2024-11-21 OncoC4, Inc. Ph-sensitive anti-ctla-4 antibodies and uses thereof
EP4534101A1 (en) 2023-10-02 2025-04-09 Eli Lilly and Company Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4379166A (en) * 1981-08-03 1983-04-05 Schering Corporation Arylmethoxy-, arylmethylthio-, heteroarylmethoxy-, and heteroarylmethylthio-alkylaminoalcohols
AT399874B (de) * 1990-06-05 1995-08-25 Glaxo Group Ltd Dichloranilinverbindung
FR2676058B1 (fr) * 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
EP0647450A1 (en) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
EP1880737A1 (fr) * 1994-08-19 2008-01-23 La Region Wallonne Composés, composition pharmaceutique et dispositif de diagnostic les comprenant et leur utilisation
FR2852606A1 (fr) * 2003-03-18 2004-09-24 Inst Nat Sante Rech Med Moyens pour inhiber simultanement l'expression de plusieurs genes impliques dans une pathologie
WO2005115105A2 (en) * 2004-05-10 2005-12-08 Northwestern University Self-immolative magnetic resonance imaging contrast agents sensitive to beta-glucuronidase
EP2098533A1 (en) 2008-03-07 2009-09-09 Pharmachemie B.V. Esters of glucuronide prodrugs of anthracyclines and method of preparation and use in tumor-selective chemotherapy

Also Published As

Publication number Publication date
CA2799773A1 (fr) 2011-11-24
JP2013532132A (ja) 2013-08-15
EP2571528A1 (fr) 2013-03-27
US9000135B2 (en) 2015-04-07
US20130144045A1 (en) 2013-06-06
CA2799773C (fr) 2019-10-22
ES2666562T3 (es) 2018-05-07
WO2011145068A1 (fr) 2011-11-24
EP2571528B1 (fr) 2018-01-31
FR2960153B1 (fr) 2012-08-17
FR2960153A1 (fr) 2011-11-25

Similar Documents

Publication Publication Date Title
JP6223824B2 (ja) 新規な自己反応性アーム及び同物を含むプロドラッグ
JP6892694B2 (ja) 癌選択性標識化及び標的指向化のためのトリガー活性型代謝糖前駆体
JP2020507584A (ja) 癌選択的標識および標的化のためのトリガー活性化可能な糖コンジュゲート
CN119013250A (zh) 可电离阳离子脂质和脂质纳米颗粒
PT99954B (pt) Processo de preparacao de moleculas de ligacao labeis aos acidos e de composicoes farmaceuticas
KR102840665B1 (ko) 세포독성 약물의 접합체 및 상기 접합체의 전구약물 형태
CN114917358A (zh) 用于治疗癌症和炎症性疾病的偶联物和前药
US8637468B2 (en) Synthetic cholesterylamine-linker derivatives for agent delivery into cells
Zhang et al. Novel galactosylated poly (ethylene glycol)-cholesterol for liposomes as a drug carrier for hepatocyte-targeting
BR112021012713A2 (pt) Distribuição direcionada de moléculas terapêuticas
EP1986700A2 (en) The staudinger reaction in imaging and therapy and kits for use in imaging and therapy
CN108472387A (zh) 双官能前药
CN113321698B (zh) 一种单甲基澳瑞他汀e前药及其制备方法和应用
WO2017176648A1 (en) Topoisomerase poisons
US20250161506A1 (en) Antibody Drug Conjugate Based on Metal N-Heterocyclic Carbene Complex, a Method of Preparing the Same and the Use of the Same in Anticancer Treatment
US20250269044A1 (en) Psma-targeted dendrimer nanoplatform for cancer detection and therapy
JP7749247B2 (ja) 癌治療のための標的化アントラサイクリン送達システム
CN119971065A (zh) 含毛兰素的抗体药物偶联物及其制备方法和应用
CZ309740B6 (cs) Glykopolymer, způsob jeho přípravy a jeho použití jako léčivo
CN119744179A (zh) 用于靶向疗法的偶联物
Xia Design and Synthesis of Doxorubicin Conjugated Gold Nanoparticles as Anticancer Drug Delivery System
CN111973555A (zh) 抗肿瘤和抗肿瘤转移的双pH敏感聚合物-药物偶联物混合胶束组合物
HK1213773B (en) Branched linker for protein drug conjugates
EA043080B1 (ru) Конъюгат цитотоксического лекарственного средства и пролекарственная форма указанного конъюгата
Sonntagbauer Design and evaluation of novel anthracycline derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140509

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20151005

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160810

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20161014

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20161222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170721

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171004

R150 Certificate of patent or registration of utility model

Ref document number: 6223824

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250